Scientific Advisory Boards

Scientific Advisory Boards provide expert input to each of the disease and organization reports. The Boards help to identify current areas of research, research challenges, and investment priorities. They also provide input as to how each organizations’ activities are aligned with the needs of the field and the relevance of their contributions. 

Alzheimer’s Disease Scientific Advisory Board

  • Christopher Austin, MD, Senior Advisor for Translational Research, National Human Genome Research Institute
  • Jeffrey Cummings, MD, Professor of Neurology and Psychiatry; Director, Alzheimer Disease Research Center, University of California, Los Angeles
  • William Potter, MD, PhD, Vice President Translational Neurosicences, Merck Research Laboratories, Merck & Co., Inc.
  • John Trojanowski, MD, PhD, Professor of Geriatric Medicine and Gerontology; Director, NIA Alzheimer’s Disease Core Center; Co-director, Center for Neurodegenerative Disease Research and Marian S. Ware Alzheimer Drug Discovery Program, University of Pennsylvania

Malaria Scientific Advisory Board

  • Francois Bompart, MD, Vice President, Medical, Access to Medicines, Sanofi-Aventis
  • Carl Craft, former Chief Scientific Officer, Medicines for Malaria Venture
  • Dr. Christopher Plowe, Professor and Chief, Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine
  • Elizabeth Winzeler, PhD, Department Head, Genomics Institute of the Novartis Research Foundation; Associate Professor, Department of Cell Biology, The Scripps Research Institute
  • Peter Zimmerman, PhD, Associate Professor, Center for Global Health & Diseases, Case Western University

Multiple Sclerosis Scientific Advisory Board

  • Steve Arkinstall, PhD, Vice President and Head of US Research, EMD Serono
  • Henry McFarland, MD, Chief, Neuroimmunology Branch, NINDS, NIH
  • Moses Rodriquez, MD, Professor of Immunology, Professor of Neurology, Department of Neurology, Mayo Clinic
  • Bruce Trapp, PhD, Chairman, Neurosciences, Cleveland Clinic
  • Robert Weissert, MD, PhD, Head of Business and Scientific Liaison, Therapeutic Area Neurodegeneration EMD Serono

Tuberculosis Scientific Advisory Board

  • Bill Jacobs, PhD, Investigator and Professor, Howard Hughes Medical Institute, Albert Einstein College of Medicine
  • Carl Nathan, MD, Professor of Medicine, Professor of Microbiology and Immunology, R.A. Rees Pritchett Professor of Microbiology, Weill Cornell Medical College
  • Phillip Prokocimer, MD, Chief Medical Officer, Trius Pharmaceuticals
  • Christine Sizemore, PhD, Chief, Tuberculosis, Leprosy and other Mycobacterial, Diseases Section, Respiratory Diseases Branch, DMID, NIAID, NIH, DHHS